All News

APLAR on red background

PAH diagnosis and management in the context of CTD ILD

Aurelie Najm, MD, PhD

Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders. Approximately 25% of patients with PAH have an underlying CTD, making CTD-PAH the second most common cause of PAH. During the session on Management of Lung Complications in CTD at APLAR 2025, Prof. Dinesh Khanna and Masataka Kuwana provided an excellent overview of PAH diagnosis and management strategies the context of CTD-ILD.

Read Article
guidelines.recommendations.jpg

ERS/EULAR guidelines for CTD-related interstitial lung disease

Jack Cush, MD

The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in the European Respiratory Journal and Annals of Rheumatic Diseases.

Read Article
APLAR on blue background

APLAR 2025: What’s New in RA Management?

Aurelie Najm, MD, PhD

The unveiling of the updated 2025 recommendations for RA treatment, presented by Josef Smolen in the plenary session on the first day of the conference, sparked attention. Although not yet formally published, these updated recommendations represent a refined consensus that simplifies decision-making while reinforcing the importance of treat-to-target principles in RA.

Read Article
many heads

Addressing Disparities and Unequal Burdens in ILD

Deji Adegunsoye, MD, PhD, FACP, FCCP

Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one  unifying truth: they are almost always serious, progressive, and life-altering. But for many patients,  the burden of disease does not fall evenly. We are increasingly learning that where you live, who  you are, and the resources available to you, can strongly influence how ILD develops and  worsens. Understanding these disparities is not about pointing fingers. Rather, it is about uncovering opportunities to deliver better, fairer care.

Read Article
Stay sharp in RA, PsA & SpA care. Get the latest breakthroughs + expert insights at RWCS 2026. Don’t miss 'Year in Review: Rheumatology Advances.' Register now: https://t.co/majEsY4tXK https://t.co/fgGniR1OGk

Links:

RWCS RWCSmtg ( View Tweet)
Where are we now—and where are we going in ILD treatment? 📅 September 9 (TONIGHT!)| ⏰ 7PM EST (LIVE) Rheumatology leaders Drs. Sindhu Johnson, Dr. Anna-Maria Hoffmann-Vold, Dr. Scott Matson, and Dr. Jack Cush will review the latest ACR & EULAR guidelines on interstitial lung https://t.co/E30AirP5WX
Dr. John Cush RheumNow ( View Tweet)
September to Remember (9.5.2025) Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD. https://t.co/dPdweMaJuN https://t.co/aExU5kV26Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Based on a survey in Japan, resolution of dry mouth was the most important symptom resolution reported by SJD pts. The JCR CPG for SjD suggests RTX for glandular involvement while BEL for extra-glandular involvements. #APLAR25 @RheumNow https://t.co/SsUvQIM9Eu

Links:

sheila RHEUMarampa ( View Tweet)
Is it D2T RA or Clinical inertia? Concept introduced by Dr Kaneko, Japanese Keio RA cohort, followed for 5yrs 5% patients not fitting the D2T RA definition have MDA or HDA The drivers of persistent DA in RA: -overestimation of treatment effectiveness -avoidance of treatment https://t.co/0pkDaUFH4R

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Interesting data shared by Dr. Sandhya Pulukool on Asian pts with SjD vs. Caucasians: - Younger age of onset except in Japan - Higher female to male ratio @RheumNow #APLAR25 https://t.co/RPM9zI4tVQ

Links:

sheila RHEUMarampa ( View Tweet)
Prof Takeuchi on DMARDs treatment and regional disparities For similar dose, serum concentration of the polyglutamate (active) form of MTX is much higher in Japanese than US patients And also high levels achieved much quicker in Japanese than US patients This is strong https://t.co/ikp63wWifj

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
What’s new in RA Pathogenesis in #APLAR25 by Ellen Gravellese Take home message: there is still hope for synovial biopsies to be a biomarker for prediction of response to treatment As a synovial biopsy expert, I am not convinced of this one, but time will tell @APLAR_org https://t.co/EEw5ncKa1r

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Can we prevent #rheumatoidarthritis? Dr. Gravallese shares this interesting slide that summarizes the different disease prevention trials in RA…..they have managed to delay disease onset but prevention is still in question. @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/qhGYnNL5Ek

Links:

sheila RHEUMarampa ( View Tweet)
🌐 ILD Treatment Guidelines – LIVE Webinar 📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies. Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Josef Smolen discusses 2025 EULAR updates for RA. He highlighted the importance of OP A - that tx should be a shared decision making between px and rheuma in order to ensure better care and disease control. @RheumNow #aplar25 #APLAR25 https://t.co/KOJbiK87TS

Links:

sheila RHEUMarampa ( View Tweet)
ACR Concerns on the Scientific Integrity at the CDC On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to https://t.co/P2J7eZN07W
Dr. John Cush RheumNow ( View Tweet)
🌐 ILD Treatment Guidelines – LIVE Webinar 📅 Sept 9 | ⏰ 7PM EST An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies. Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator https://t.co/2F3sOjqHtr #ILD https://t.co/KaVL1pUdCh

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Be Careful What You Look For Dr. Bryant England, University of Nebraska, presents this QD Clinic, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/avxw86CGqu https://t.co/5SH3p05Rlf

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR & European Respiratory Society have published clinical practice guidelines for ILD assoc w/ connective tissue diseases (SSc, RA, SjD, IIM, SLE, MCTD). 2 publications included Dz specific ILD management algorithms; use of Hi Res CT over Lung Bx; ILD risk factors

Dr. John Cush RheumNow ( View Tweet)

EHR analysis of Alaska Tribal Health System finds the prevalence of Sjögren's disease at 199 per 100K adults (primary SjD 129; secondary 70 (RA,SLE)). The age-adjusted incidence 16.6 per 100K Pt-Yrs. Only 5% had salivary gland Bx & 3% met 2016 ACR/EULAR or 2012 ACR criteria https://t.co/4tMdWIGTEi
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×